advertisement
Abstract #8488 Published in IGR 5-1
Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina
Goto W; Ota T; Morikawa N; Otori Y; Hara H; Kawazu K; Miyawaki N; Tano YBrain Research 2002; 958: 10-19
The purpose of this study was to determine whether timolol, an ocular hypotensive drug, has retinal neuroprotective effects in experimental in vitro and in vivo models. For in vitro studies, the authors used retinal neuron cultures from rat embryos and purified retinal ganglion cells (RGCs) from newborn rats. In the former, neurotoxicity was induced using 1 mM glutamate and cell viability was assessed. In RGCs, neurotoxicity was induced using 25 μM glutamate for three days and cell viability was assessed. For the in vivo study, they used a rat model of retinal ischemic injury induced by elevating intraocular pressure (IOP) by raising the hydrostatic pressure. The retinal damage was evaluated by counting the number of cells in the ganglion cell layer (GCL) and by examining the a- and b-waves in the electroretinogram (ERG). For the intraocular distribution study, 0.5% [3H]timolol was topically applied to rat eyes, and these were enucleated after various intervals and divided into parts. Each part was combusted and the radioactivity measured. Timolol (0.1 and 1 μM) markedly reduced the glutamate-induced neuronal cells in retinal neuron cultures and in RGCs. After ischemic-reperfusion, both the number of cells in the GCL and a- and b-waves in the ERG decreased; however, topically applied 0.5% timolol reduced these effects. Topically applied 0.5% timolol was detected at a concentration of ˜1 μg/g wet tissue in retina-choroid at 30 minutes after its application. In conclusion, timolol was effective against retinal neuron damage both in vitro and in vivo. Furthermore, topically applied timolol reached the retina-choroid. These findings suggest that timolol has a direct neuroprotective effect against retinal damage.
Dr. H. Hara, Glaucoma Group, Ophthalmic Research Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma 630-0101, Japan. hideaki.hara@santen.co.jp
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
